Evidence-graded deal flow in human performance.
We grade the sport, longevity and preventive-health universe on clinical evidence and unit economics — so a small circle of institutions can invest on data, not instinct.
Global longevity market — Pitchbook data and internal calculations.
of dealflow is early-stage — where evidence is thinnest and most calls are still made on instinct.
behind AI in capital-market maturity. In AI, late rounds absorb ~80% of venture dollars — this niche is only starting to grow.
Three markets are converging into one investable category.
Sports science, performance analytics, recovery tech, team & athlete services.
Clinics, diagnostics, biomarkers, healthspan therapeutics, NAD+/senolytics.
Wearables, continuous monitoring, precision nutrition, employer health, mental health.
Every existing player covers only a part.
Venture & PE funds
- Thesis-bound: must specialise to raise
- Cover 30–80 names, not 5,000
- Cannot share dealflow
- Conflicted: sell you the deal they own
Advisors
- Coverage stops when the mandate ends
- No continuous grading of the field
- No early-stage or clinic-scale assets
- Structurally biased
Data platforms
- CB Insights $30–100k, PitchBook $12–70k/yr
- Breadth without judgement — no grade
- No clinical-evidence assessment
- No access, no allocation, no deal
Our model, briefly.
Subscription research
Clients pay for coverage and judgement, monthly or annually. Revenue is recurring and independent of deal outcomes.
A grading system
Every tracked company carries two scores: clinical evidence and unit economics. Refreshed quarterly and versioned.
A deal desk
The best-graded opportunities are packaged as decision-ready memos. Clients invest on their own, or alongside us.
A fund
No committed capital, no LPs, no management fee, no deployment pressure, no fund-life clock forcing bad entries.
A broker
We do not solicit investors for issuers or take success fees on capital raised — see the regulatory page.
A generalist database
One niche, covered exhaustively. Depth is the product; breadth of sectors is what we deliberately give up.
Judgement is the product. Every company we track carries two scores — clinical evidence and unit economics — refreshed quarterly, versioned, and defensible. When green appears on our map, it means one thing: invest-grade.
From 5,000 companies to a handful of decisions.
5,000+ companies, continuous
- US, Europe, Asia, Gulf
- Sports science, recovery, wearables, diagnostics, longevity clinics, precision health
- Sources: filings, trial registries, clinic P&Ls, distributor channel, founder network
Two scores, one scale
- Clinical evidence: trials, endpoints, replication
- Unit economics: CAC, retention, gross margin, payback, capital intensity
- Re-scored quarterly, versioned
Decision-ready
- Quarterly landscape map
- Company one-pagers + grades
- Deal memos: thesis, risks, valuation, exit paths
- Analyst access on call
50–200 institutions, not a crowd
- Family offices & HNWI
- Strategics & corporates
- PE funds
- They invest on their own — or alongside us
Feedback loop: client questions, portfolio gaps and passed deals re-prioritise next quarter's coverage
How 500+ names stay current.
Great science, broken model. Watch for a strategic buyer.
Strong evidence and economics. This is the deal memo pool.
Neither. ~60% of the universe, including most viral brands.
Sells well, evidence thin. Regulatory and reputational risk.
What a client actually receives.
- Quarterly landscape map of the niche
- Full graded database, 500+ names
- Monthly written market note
- 4 analyst hours per month
- Deal memos on a 15-day delay
- Everything in Coverage
- Deal memos at publication, first look
- Two deep-dive researches per year
- Direct analyst line, 48h SLA
- Co-invest access where available
- Everything in Partner
- Custom coverage mandate & watchlist
- M&A target screening and outreach
- Board-ready diligence packs
- On-site quarterly review
Questions we hear from allocators.
There is no committed capital, no LPs, no management fee and no deployment clock. Clients pay for coverage and judgement; whether any deal happens afterwards is their decision, made on their own account.
No. Our revenue is the subscription and, occasionally, fixed-fee diligence mandates. We do not solicit investors for issuers — which is exactly what keeps the research conflict-light.
In a minority of deals we recommend, we may invest our own personal balance sheet on the same terms as clients. It is always disclosed in the memo and never a condition of access.
A quarterly landscape map, the re-scored database of 500+ names, a monthly written market note and 20–30 deal memos a year — plus direct analyst hours, depending on tier.
Yes. Most clients start on Coverage, watch two or three memo cycles, then move to Partner when they want first-look access and the direct analyst line.
Humane sells subscription research and analysis. We are not a fund and not a broker: we hold no client capital, do not solicit investors for issuers, and take no success fees on capital raised. Nothing on this site is investment advice or an offer of securities.